Operating
Stemcentrx Impairment Charge
Dollar Tree Stemcentrx Impairment Charge remained flat by 0.0% to $2.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 82.7%, from $13.03M to $2.25M. Over 4 years (FY 2021 to FY 2025), Stemcentrx Impairment Charge shows an upward trend with a 19.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2021
Last reportedQ4 2025Mar 16, 2026
Metric ID:
abbv_stemcentrx_impairmentHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $4.4M | $1.5M | $10.9M | $52.1M | $9M |
| YoY Change | — | -65.9% | +626.7% | +378.0% | -82.7% |
Range$1.5M – $52.1M
CAGR+19.6%
Avg YoY Growth+214.0%
Median YoY Growth+156.0%
Stemcentrx Impairment Charge at Other Companies
Frequently Asked Questions
- What is Dollar Tree's stemcentrx impairment charge?
- Dollar Tree (DLTR) reported stemcentrx impairment charge of $2.25M in Q4 2025.
- How has Dollar Tree's stemcentrx impairment charge changed year-over-year?
- Dollar Tree's stemcentrx impairment charge decreased by 82.7% year-over-year, from $13.03M to $2.25M.
- What is the long-term trend for Dollar Tree's stemcentrx impairment charge?
- Over 4 years (2021 to 2025), Dollar Tree's stemcentrx impairment charge has grown at a 19.6% compound annual growth rate (CAGR), from $4.4M to $9M.